Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207015 | 0.86 | MAPT (0.41) | MCHR1CHRM1HTR2AMAPTMEN1 | |
| SCHEMBL5211936 | 0.85 | MAPT (0.42) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL5207462 | 0.83 | MAPT (0.41) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL5208383 | 0.82 | SMO (0.43) | MAPTMEN1KMT2AALDH1A1PARP3 | |
| SCHEMBL5211798 | 0.82 | CHRM1 (0.40) | ADCY1MCHR1CHRM1HTR2AMAPT | |
| SCHEMBL5207600 | 0.81 | TP53 (0.44) | ADCY1MAPTMEN1KMT2ALMNA | |
| SCHEMBL5213773 | 0.81 | PIK3CA (0.41) | MCHR1MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL5215005 | 0.81 | PARP3 (0.39) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL5208991 | 0.81 | MAPT (0.39) | MCHR1CHRM1HTR2AMAPTMEN1 | |
| SCHEMBL5207440 | 0.80 | CETP (0.47) | MAPTMEN1KMT2AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | ADCY1 1793/4885MCHR1 1777/4885CHRM1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.